Your browser doesn't support javascript.
Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2.
Naushin, Salwa; Sardana, Viren; Ujjainiya, Rajat; Bhatheja, Nitin; Kutum, Rintu; Bhaskar, Akash Kumar; Pradhan, Shalini; Prakash, Satyartha; Khan, Raju; Rawat, Birendra Singh; Tallapaka, Karthik Bharadwaj; Anumalla, Mahesh; Chandak, Giriraj Ratan; Lahiri, Amit; Kar, Susanta; Mulay, Shrikant Ramesh; Mugale, Madhav Nilakanth; Srivastava, Mrigank; Khan, Shaziya; Srivastava, Anjali; Tomar, Bhawana; Veerapandian, Murugan; Venkatachalam, Ganesh; Vijayakumar, Selvamani Raja; Agarwal, Ajay; Gupta, Dinesh; Halami, Prakash M; Peddha, Muthukumar Serva; Sundaram, Gopinath M; Veeranna, Ravindra P; Pal, Anirban; Agarwal, Vinay Kumar; Maurya, Anil Ku; Singh, Ranvijay Kumar; Raman, Ashok Kumar; Anandasadagopan, Suresh Kumar; Karuppanan, Parimala; Venkatesan, Subramanian; Sardana, Harish Kumar; Kothari, Anamika; Jain, Rishabh; Thakur, Anupama; Parihar, Devendra Singh; Saifi, Anas; Kaur, Jasleen; Kumar, Virendra; Mishra, Avinash; Gogeri, Iranna; Rayasam, Geethavani; Singh, Praveen.
  • Naushin S; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Sardana V; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Ujjainiya R; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Bhatheja N; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Kutum R; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Bhaskar AK; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Pradhan S; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Prakash S; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Khan R; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Rawat BS; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Tallapaka KB; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Anumalla M; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Chandak GR; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Lahiri A; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Kar S; CSIR-Advanced Materials and Processes Research Institute, Bhopal, India.
  • Mulay SR; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Mugale MN; CSIR-Central Building Research Institute, Roorkee, India.
  • Srivastava M; CSIR-Centre for Cellular Molecular Biology, Hyderabad, India.
  • Khan S; CSIR-Centre for Cellular Molecular Biology, Hyderabad, India.
  • Srivastava A; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Tomar B; CSIR-Centre for Cellular Molecular Biology, Hyderabad, India.
  • Veerapandian M; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Venkatachalam G; CSIR-Central Drug Research Institute, Lucknow, India.
  • Vijayakumar SR; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Agarwal A; CSIR-Central Drug Research Institute, Lucknow, India.
  • Gupta D; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Halami PM; CSIR-Central Drug Research Institute, Lucknow, India.
  • Peddha MS; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Sundaram GM; CSIR-Central Drug Research Institute, Lucknow, India.
  • Veeranna RP; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Pal A; CSIR-Central Drug Research Institute, Lucknow, India.
  • Agarwal VK; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Maurya AK; CSIR-Central Drug Research Institute, Lucknow, India.
  • Singh RK; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Raman AK; CSIR-Central Drug Research Institute, Lucknow, India.
  • Anandasadagopan SK; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Karuppanan P; CSIR-Central Drug Research Institute, Lucknow, India.
  • Venkatesan S; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Sardana HK; CSIR-Central Electrochemical Research Institute, Karaikudi, India.
  • Kothari A; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Jain R; CSIR-Central Electrochemical Research Institute, Karaikudi, India.
  • Thakur A; CSIR-Central Electrochemical Research Institute, Karaikudi, India.
  • Parihar DS; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Saifi A; CSIR-Central Electronics Engineering Research Institute, Pilani, India.
  • Kaur J; CSIR-Central Electronics Engineering Research Institute, Pilani, India.
  • Kumar V; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Mishra A; CSIR-Central Food Technological Research Institute, Mysore, India.
  • Gogeri I; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Rayasam G; CSIR-Central Food Technological Research Institute, Mysore, India.
  • Singh P; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Elife ; 102021 04 20.
Article in English | MEDLINE | ID: covidwho-1194809
ABSTRACT
To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value 2.23, 1.92-2.59, <0.0001), use of public transport (1.79, 1.43-2.24, <0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, <0.0001), and B blood group (1.36, 1.15-1.61, 0.001).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Year: 2021 Document Type: Article Affiliation country: ELife.66537

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Year: 2021 Document Type: Article Affiliation country: ELife.66537